Trial Profile
A Phase Ib, Open-label, Multi-center, Dose-escalation and Expansion Study of an Orally Administered Combination of BEZ235 Plus MEK162 in Adult Patients With Selected Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Binimetinib (Primary) ; Dactolisib (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis
- 26 Feb 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 24 Jul 2012 Additional lead trial investigators and associated centres added as reported by ClinicalTrials.gov.
- 25 Apr 2012 Planned number of patients changed from 65 to 80 as reported by ClinicalTrials.gov.